Trial · NCT03055377

N-Acetylcysteine for Youth Cannabis Use Disorder

NCT03055377, Phase 2, Phase 3, Completed, Medical University of South Carolina; results first posted 2024-12-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. N-Acetylcysteine for Youth Cannabis Use Disorder. Trials, record NCT03055377. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03055377

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: N-Acetylcysteine for Youth Cannabis Use Disorder
NCT number: NCT03055377
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 192 participants, actual
Lead sponsor: Medical University of South Carolina
Conditions: Cannabis Use Disorder
Interventions: N-acetyl cysteine, Placebo oral capsule
First posted: 2017-02-16
Last updated: 2024-12-17
Results first posted: 2024-12-17

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of Urine Tests With Negative Cannabinoid Results During Treatment	Weekly urine cannabinoid tests during 12-week active treatment	Qualitative urine cannabinoid testing, with cutoff of 50 ng/mL

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage of Urine Tests With Negative Cannabinoid Results During Treatment	Weekly urine cannabinoid tests during 12-week active treatment	Enrolled and randomized participants	Percentage	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Percentage of Urine Tests With Negative Cannabinoid Results During Treatment	N-acetylcysteine		9.4		Percentage
Percentage of Urine Tests With Negative Cannabinoid Results During Treatment	Placebo		14.0		Percentage

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Treatment Phase	STARTED	N-acetylcysteine	98
Treatment Phase	STARTED	Placebo	94
Treatment Phase	COMPLETED	N-acetylcysteine	70
Treatment Phase	COMPLETED	Placebo	70
Treatment Phase	NOT COMPLETED	N-acetylcysteine	28
Treatment Phase	NOT COMPLETED	Placebo	24
Post-Treatment Follow-Up	STARTED	N-acetylcysteine	70
Post-Treatment Follow-Up	STARTED	Placebo	70
Post-Treatment Follow-Up	COMPLETED	N-acetylcysteine	44
Post-Treatment Follow-Up	COMPLETED	Placebo	49

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events246

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Palpitations	Cardiac disorders	N-acetylcysteine	0	98	0
other	Palpitations	Cardiac disorders	Placebo	1	94	1
other	Lymphadenopathy	Blood and lymphatic system disorders	N-acetylcysteine	1	98	1
other	Lymphadenopathy	Blood and lymphatic system disorders	Placebo	1	94	1
other	Ear Congestion	Ear and labyrinth disorders	N-acetylcysteine	2	98	2
other	Ear Congestion	Ear and labyrinth disorders	Placebo	1	94	1
other	Otitis Media	Ear and labyrinth disorders	N-acetylcysteine	0	98	0
other	Otitis Media	Ear and labyrinth disorders	Placebo	1	94	1
other	Conjunctivitis	Eye disorders	N-acetylcysteine	1	98	1
other	Conjunctivitis	Eye disorders	Placebo	0	94	0

1 to 10 of 246Source ClinicalTrials.gov

See all 246 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	N-acetylcysteine	0	98
Total, all-cause mortality	Placebo	0	94
Total, other adverse events	N-acetylcysteine	86	98
Total, other adverse events	Placebo	73	94
Total, serious adverse events	N-acetylcysteine	0	98
Total, serious adverse events	Placebo	0	94

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
39910268	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
N-acetylcysteine vs Placebo: deaths from any cause	Trial comparisons
N-acetylcysteine vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03055377

GET https://conductscience.org/api/trials/v1/NCT03055377/events?page=2

API reference For AI assistants